Hugel Inc (145020 KS): Achieves Record High Revenue and Operating Profit in 4Q23
Hugel has received FDA approval for its botulinum toxin Letybo and becomes the only Korean company and one of the top 3 players globally that have...
501 Views
Hugel Inc (145020 KS): Achieves Record High Revenue in 2Q23; Resubmits Marketing Application in US
Hugel reports 28% growth in revenue and operating profit in 2Q23, driven by toxins and fillers. They have resubmitted botulinum toxin BLA in the...
425 Views
Hugel: A Solid Turnaround Story With Resumption of Botulax Sales in China
Hugel is a solid turnaround story. The recent resumption of its Botulax product sales in China is likely to boost the company's sales and profits...
329 Views
Hugel Inc (145020 KS): Expanding Global Presence Provides Solace Amid Patent Tussle with Competitor
Hugel is expected to resume shipment of Botulax to China this month and will enter Canada and some European markets this year. The company is in...
293 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
574 Views